(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 174.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Absci's revenue in 2025 is $4,138,000.On average, 4 Wall Street analysts forecast ABSI's revenue for 2025 to be $1,133,531,187, with the lowest ABSI revenue forecast at $627,995,117, and the highest ABSI revenue forecast at $2,186,768,712. On average, 4 Wall Street analysts forecast ABSI's revenue for 2026 to be $7,171,106,150, with the lowest ABSI revenue forecast at $1,450,369,676, and the highest ABSI revenue forecast at $11,513,243,819.
In 2027, ABSI is forecast to generate $12,737,086,685 in revenue, with the lowest revenue forecast at $10,915,153,231 and the highest revenue forecast at $15,194,491,388.